All In Biotech

Drug Trial Radar · NCT06017609

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of JTT-861 Administered for 12 Weeks in Subjects With Heart Failure With Reduced Ejection Fraction

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 314 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

314

Actual

Start

Dec 20, 2023

Primary completion

May 18, 2026

Study completion May 18, 2026

Sponsor

Lead sponsor
Shionogi Inc.Industry
Sponsor type
Industry
Collaborators
ICON Clinical Research
First posted
Aug 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.

Conditions

  • Chronic Heart Failure

Interventions

  • JTT-861 CapsulesDrug

    Active drug capsules containing JTT-861

  • Placebo CapsulesDrug

    Placebo capsules matching in appearance to the active drug capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to end of treatment (EOT) in left ventricular ejection fraction (LVEF) as assessed by two-dimensional echocardiography (2D-echo)Time frame: 12 Weeks
  2. Change from baseline to EOT in left ventricular end-systolic volume (LVESV) index as assessed by 2D-echoTime frame: 12 Weeks
  3. Change from baseline to EOT in left ventricular end-diastolic volume (LVEDV) index as assessed by 2D-echoTime frame: 12 Weeks
  4. Change from baseline to EOT in left atrial volume (LAV) as assessed by 2D-echoTime frame: 12 Weeks
  5. Change from baseline to EOT in N-terminal pro b-type natriuretic peptide (NT-pro-BNP) valuesTime frame: 12 Weeks
  6. Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores from baselineTime frame: 16 Weeks
  7. Number of subjects with treatment-emergent adverse eventsTime frame: Up to 16 Weeks
  8. Trough plasma concentrations of JTT-861Time frame: Weeks 4, 8 and 12
  9. Post-dose plasma concentrations of JTT-861Time frame: Weeks 2, 4 and 8

Locations

75 sites in 6 countries. Site status is shown where the registry gives one.

  • Arensia Exploratory Medicine Inc.

    Phoenix, Arizona

  • Nature Coast Clinical Research

    Crystal River, Florida

  • Indago Research & Health Center, Inc.

    Hialeah, Florida

  • Med Research of Florida

    Miami, Florida

  • Pharma Medical Innovation, Inc.

    Miami Lakes, Florida

  • Floridian Clinical Research

    Miami Lakes, Florida

  • Affinity Health

    Park Ridge, Illinois

  • ASHA Clinical Research-Munster, LLC

    Hammond, Indiana

  • Monroe Research, LLC

    West Monroe, Louisiana

  • Henry Ford Hospital

    Detroit, Michigan

  • Profound Research LLC

    Farmington Hills, Michigan

  • NextStage Clinical Research - (Kansas City [01])

    Kansas City, Missouri

  • Laurelton Heart Specialist P.C.

    Rosedale, New York

  • Capital Area Research, LLC

    Camp Hill, Pennsylvania

  • Onsite Clinical Solutions, LLC

    Rock Hill, South Carolina

  • NextStage Clinical Research-Beaumont- (01)

    Beaumont, Texas

  • Cypress Heart and Vascular Center

    Cypress, Texas

  • NextStage Clinical Research-Port Arthur-(02)

    Port Arthur, Texas

  • Sherman Clinical Research

    Sherman, Texas

  • Waco Cardiology Associates - NextStage Clinical Research

    Waco, Texas

  • Ambulatory for Specialized Outpatient Medical Care in Cardiology Individual Practice- Dr. Elena Dotcheva EOOD

    Burgas, Bulgaria

  • Multiprofile Hospital for Active Treatment "Ivan Skenderov"

    Gotse Delchev, Bulgaria

  • Multiprofile Hospital For Active Treatment Ivan Skenderov EOOD

    Gotse Delchev, Bulgaria

  • University Multiprofile Hospital for Active Treatment Georgi Stranski, EAD

    Pleven, Bulgaria

  • Multiprofile Hospital For Active Treatment Heart and Brain EAD

    Pleven, Bulgaria

  • University Multiprofile Hospital For Active Treatment Saint Georgi EAD

    Plovdiv, Bulgaria

  • Acibadem City Clinic University Multiprofile Hospital For Active Treatment EOOD

    Sofia, Bulgaria

  • Medical Center Hera EOOD

    Sofia, Bulgaria

  • Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD

    Sofia, Bulgaria

  • Diagnostic Consultative Center Convex EOOD

    Sofia, Bulgaria

  • University Multiprofile Hospital for Active Treatment. Sv Anna - Sofia AD

    Sofia, Bulgaria

  • MUDr. Libor Nechvatal s.r.o.

    Brno, Czechia

  • Centrum pro zdraví, s.r.o.

    Brno, Czechia

  • Vojenská nemocnice Brno

    Brno, Czechia

  • Fakultní nemocnice Brno

    Brno, Czechia

  • Edumed s.r.o.

    Broumov, Czechia

  • Edumed s.r.o.

    Hradec Králové, Czechia

  • Edumed s.r.o.

    Jaroměř, Czechia

  • Edumed s.r.o.

    Náchod, Czechia

  • Fakultní nemocnice Ostrava

    Ostrava-Poruba, Czechia

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.